Nefopam as an alternative to nonsteroidal anti-inflammatory drugs in perioperative pain management: a narrative review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the foundation of contemporary perioperative pain management regimens. However, their use is often limited by a broad range of serious adverse effects and contraindications. This review, based on an analysis of the scientific sources, aims to evaluate the analgesic efficacy and safety of nefopam, a centrally acting non-opioid analgesic, as an alternative to NSAIDs in perioperative pain management regimens. A search of medical databases, including PubMed (MEDLINE), the Cochrane Library, and eLibrary (RSCI), was conducted from July 1 to December 30, 2024. Nefopam has demonstrated consistent analgesic and opioid-sparing effects in laparoscopic surgery, spinal surgery, cardiac surgery, and transplantation, as well as in patients in intensive care units. Additional beneficial effects include prevention and treatment of postoperative shivering and reduction of discomfort and pain associated with urinary catheterization. The most commonly reported adverse effects of nefopam include excessive sweating, tachycardia following intravenous administration, and dry mouth. Overall, nefopam appears to have a more favorable safety profile compared with NSAIDs.

About the authors

Аlexei М. Ovechkin

Sechenov First Moscow State Medical University

Author for correspondence.
Email: ovechkin_alexei@mail.ru
ORCID iD: 0000-0002-3453-8699
SPIN-code: 1277-9220

MD, Dr. Sci. (Medicine), Department Professor

Russian Federation, Moscow

Mikhail E. Politov

Sechenov First Moscow State Medical University

Email: politov_m_e@staff.sechenov.ru
ORCID iD: 0000-0003-0623-4927
SPIN-code: 2048-9705
Scopus Author ID: 57204015597

MD, Cand. Sci. (Medicine), Associate Professor

Russian Federation, Moscow

Vladimir F. Petrovskii

Sechenov First Moscow State Medical University

Email: 4sr15@mail.ru
ORCID iD: 0009-0006-1561-1033

student

Russian Federation, Moscow

Maria A. Sheina

Sechenov First Moscow State Medical University

Email: sheina_m_a@staff.sechenov.ru
ORCID iD: 0009-0001-2897-4144
SPIN-code: 3647-7561

MD, Department Assistant

Russian Federation, Moscow

Sergey V. Sokologorskiy

Sechenov First Moscow State Medical University

Email: docsvs@mail.ru
ORCID iD: 0000-0001-6805-9744
SPIN-code: 8933-8819

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157. doi: 10.1016/j.jpain.2015.12.008. Erratum in: J Pain. 2016;17(4):508–510. doi: 10.1016/j.jpain.2016.02.002
  2. Ovechkin AM, Bayalieva AZh, Ezhevskaya AA, et al. Postoperative analgesia. Guidelines. Annals of Critical Care. 2019;4:9–33. doi: 10.21320/1818-474X-2019-4-9-33
  3. Schug SA, Palmer GM, Scott DA, et al. Acute pain management: scientific evidence, fourth edition, 2015. Med J Aust. 2016;204(8):315–317. doi: 10.5694/mja16.00133
  4. Elia N, Lysakowski C, Tramèr M. Does multimodal analgesia with acetaminophen, nonsteroidal anti-inflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005;103(6):1296–1304. doi: 10.1097/00000542-200512000-00025
  5. Strom B, Berlin J, Kinman J. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. JAMA. 1996;275:376–382.
  6. Forrest J, Kamu F, Greer I. Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth. 2002;88(2):227–233.
  7. Lee A, Cooper M, Craig J. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults (Cochrane Review). Cochrane Database Syst Rev. 2004;(2):CD002765. doi: 10.1002/14651858.CD002765.pub2. Update in: Cochrane Database Syst Rev. 2007;(2):CD002765. doi: 10.1002/14651858.CD002765.pub3
  8. Schjerning Olsen AM, Fosbøl E, Lindhardsen J. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–2235. doi: 10.1161/CIRCULATIONAHA.110.004671
  9. Biere-Rafi S, Di Nisio M, Gerdes V, et al. Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2011;20:635–642. doi: 10.1002/pds.2130
  10. Catella-Lawson F, Crofford L. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001;110(3A):28S–32S. doi: 10.1016/s0002-9343(00)00683-5
  11. Hakkarainen T, Steele S, Bastaworous A, et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure: a report from Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg. 2015;150(3):223–228. doi: 10.1001/jamasurg.2014.2239 Erratum in: JAMA Surg. 2015;150(5):492. doi: 10.1001/jamasurg.2015.0663
  12. Kotagal M, Hakkarainen T, Simianu V, et al. Ketorolac use and postoperative complications in gastrointestinal surgery. Ann Surg. 2016;263(1):71–75. doi: 10.1097/SLA.0000000000001260
  13. Zhao T, Shen Z, Sheng S. The efficacy and safety of nefopam for pain relief during laparoscopic cholecystectomy: a meta-analysis. Medicine (Baltimore). 2018;97(10):e0089. doi: 10.1097/MD.0000000000010089
  14. Lim H, Kang S, Kim B, Ko S. Comparison between preoperative and intraoperative administration of nefopam for acute and chronic postoperative pain in colon cancer patients: a prospective, randomized, double-blind study. World J Surg. 2019;43:3191–3197. doi: 10.1007/s00268-019-05119-3
  15. Yoon S, Lee H, Na K, et al. Effect of continuous infusion of intravenous nefopam on postoperative opioid consumption after video-assisted thoracic surgery: a double-blind randomized controlled trial. Pain Physician. 2022;25:491–500.
  16. Yeo H, Choi J, Lee S, et al. The lack of analgesic efficacy of nefopam after video-assisted thoracoscopic surgery for lung cancer: a randomized, single-blinded, controlled trial. J Clin Med. 2022;11:4849. doi: 10.3390/jcm11164849
  17. Jin S, Lee Y, Kim D, et al. Effect of nefopam on dysesthesia, postoperative pain, and satisfaction in patients with lumbar spinal stenosis undergoing spine surgery: a double-blind, randomized study. J Clin Med. 2023;12:7468. doi: 10.3390/jcm12237468
  18. Kim K, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014;27:103–111. doi: 10.3344/kjp.2014.27.2.103
  19. Ok Y, Cheon J, Choi E, Chang E, Lee H, Kim K. Nefopam reduces dysesthesia after percutaneous endoscopic lumbar discectomy. Korean J Pain. 2016;29:40–47. doi: 10.3344/kjp.2016.29.1.40
  20. Chalermkitpanit P, Yingsakmongkol W, Limthongkul W, et al. Perioperative intravenous nefopam on pain management and ambulation after open spine surgery: a randomized double-blind controlled study. Asian Spine J. 2023;17(4):632–638. doi: 10.31616/asj.2022.0358
  21. Kim K, Kim WJ, Choi DK, et al. The analgesic efficacy and safety of nefopam in patient-controlled analgesia after cardiac surgery: a randomized, double-blind, prospective study. J Int Med Res. 2014;42(3):684–692. doi: 10.1177/0300060514525351
  22. Kim SY, Huh KH, Roh YH, et al. Nefopam as an adjunct to intravenous patient-controlled analgesia after renal transplantation: a randomised trial. Acta Anaesthesiol Scand. 2015;59:1068–1075. doi: 10.1111/aas.12519
  23. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez L. Nonsteroidal anti-inflammatory drugs and risk of acute renal failure in the general population. Am J Kidney Dis. 2005;45:531–539. doi: 10.1053/j.ajkd.2004.12.005
  24. Murphy E. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005;33:311–322. doi: 10.1177/0310057X0503300306
  25. Aymard G, Warot D, Demolis P, et al. Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. Pharmacol Toxicol. 2003;92:279–286. doi: 10.1034/j.1600-0773.2003.920605.x
  26. Fecho K, Miller N, Merritt S, et al. Acute and persistent postoperative pain after breast surgery. Pain Med. 2009;10(4):708–715. doi: 10.1111/j.1526-4637.2009.00611.x
  27. Na HS, Oh AY, Koo BW, et al. Preventive analgesic efficacy of nefopam in acute and chronic pain after breast cancer surgery. Medicine (Baltimore). 2016;95(20):e3705. doi: 10.1097/MD.0000000000003705
  28. McCartney C, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg. 2004; 98(5):1385–400, table of contents. doi: 10.1213/01.ane.0000108501.57073.38
  29. Biella G, Groppetti A, Novelli A, et al. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. J Neurotrauma. 2003;20(6):593–601. doi: 10.1089/089771503767168519
  30. Jung B, Ahrendt G, Oaklander A, et al. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003;104(1-2):1–13. doi: 10.1016/s0304-3959(03)00241-0
  31. Burry L, Williamson D, Perreault M, et al. Analgesic, sedative, antipsychotic, and neuromuscular blocker use in Canadian intensive care units: a prospective, multicentre, observational study. Can J Anaesth. 2014;61(7):619–630. doi: 10.1007/s12630-014-0174-1
  32. Evans M, Lysakowski C, Tramer M. Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth. 2008;101(5):610–617. doi: 10.1093/bja/aen267
  33. Girard P, Chauvin M, Verleye M. Nefopam analgesia and its role in multimodal analgesia: a review of preclinical and clinical studies. Clin Exp Pharmacol Physiol. 2016;43(1):3–12. doi: 10.1111/1440-1681.12506
  34. Du Manoir B, Aubrun F, Langlois M, et al. Randomized prospective study of the analgesic effect of nefopam after orthopedic surgery. Br J Anaesth. 2003;91(6):836–841. doi: 10.1093/bja/aeg264
  35. Mimoz O, Incagnoli P, Josse C, et al. Analgesic efficacy and safety of nefopam vs. propacetamol following hepatic resection. Anaesthesia. 2001;56(6):520–525. doi: 10.1046/j.1365-2044.2001.01980.x
  36. Tramoni G, Viale J, Cazals C, Bhageerutty K. Morphine-sparing effect of nefopam by continuous intravenous injection after abdominal surgery by laparotomy. Eur J Anaesthesiol. 2003;20(12):990–992. doi: 10.1017/s0265021503251590
  37. Mimoz O, Chauvet S, Gregoire N. Nefopam pharmacokinetics in patients with end-stage renal disease. Anesth Analg. 2010;111(5):1146–1153. doi: 10.1213/ANE.0b013e3181f33488
  38. Wheeler K, Grilli R, Centofanti J, et al. Adjuvant analgesic use in the critically ill: a systematic review and meta-analysis. Crit Care Expl. 2020;2:e0157. doi: 10.1097/CCE.0000000000000157
  39. Devlin J, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873. doi: 10.1097/CCM.0000000000003299
  40. Payen J, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology. 2007;106(4):687–695; quiz 891-2. doi: 10.1097/01.anes.0000264747.09017.da
  41. Seo Y, Lee HJ, Ha E, Ha T. 2021 KSCCM clinical practice guidelines for pain, agitation, delirium, immobility, and sleep disturbance in the intensive care unit. Acute Crit Care. 2022;37(1):1–25. doi: 10.4266/acc.2022.00094
  42. Lewis S, Nicholson A, Smith A, Alderson P. Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia. Cochrane Database Syst Rev. 2015;2015(8):CD011107. doi: 10.1002/14651858.CD011107.pub2
  43. Crowley L, Buggy D. Shivering and neuraxial anesthesia. Reg Anesth Pain Med. 2008;33(3):241–52. doi: 10.1016/j.rapm.2007.11.006
  44. Bilotta F, Pietropaoli P, Sanita R, Liberator G, Rosa G. Nefopam and tramadol for the prevention of shivering during neuraxial anesthesia. Reg Anesth Pain Med. 2002;27(4):38–384. doi: 10.1053/rapm.2002.33563
  45. Park S, Mangat H, Berger K, Rosengart A. Efficacy spectrum of antishivering medications: meta-analysis of randomized controlled trials. Crit Care Med. 2012;40(11):3070–3082. doi: 10.1097/CCM.0b013e31825b931e
  46. Chi J, Wu J, Lou K, et al. The systematic review and meta-analysis evaluated the efficacy and safety of nefopam for catheter-related bladder discomfort based on randomized controlled trials. Front Pharmacol. 2023;14:1305844. doi: 10.3389/fphar.2023.1305844
  47. Durrieu G, Oliver P, Bagheri H. Overview of adverse reactions to nefopam: an analysis of French pharmacovigilance database. Fund Clin Pharmacol. 2007;21(5):555–558. doi: 10.1111/j.1472-8206.2007.00499.x
  48. Chanques G, Sebbane M, Constantin J, et al. Analgesic efficacy and haemodynamic effects of nefopam in critically ill patients. Br J Anaesth. 2011;106(3):336–343. doi: 10.1093/bja/aeq375
  49. Pallapies D, Peskar B, Brune K, Zeilhofer H. Modulation of nitric oxide effects by flurbiprofen enantiomers and nefopam and its relation to antinociception. Eur J Pharmacol. 1994;271:335–340. doi: 10.1016/0014-2999(94)90791-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».